SRK-015

Phase 2Completed
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinal Muscular Atrophy

Conditions

Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations

Trial Timeline

Apr 22, 2019 → Feb 28, 2024

About SRK-015

SRK-015 is a phase 2 stage product being developed by Scholar Rock Holding for Spinal Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT03921528. Target conditions include Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03921528Phase 2Completed

Competing Products

20 competing products in Spinal Muscular Atrophy

See all competitors
ProductCompanyStageHype Score
SUN13837 injection + PlaceboDaiichi SankyoPhase 2
52
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 2
52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 1
33
ElezanumabAbbViePre-clinical
23
Elezanumab + PlaceboAbbViePhase 2
52
Ropivacaine + BupivacaineAstraZenecaPhase 3
77
Onasemnogene Abeparvovec-xioiNovartisPhase 1
33
ZolgensmaNovartisPre-clinical
23
BVS857 + PlaceboNovartisPhase 2
52
AVXS-101NovartisPhase 1
33
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
Onasemnogene Abeparvovec-brveNovartisApproved
85
Onasemnogene Abeparvovec-xioiNovartisPre-clinical
23
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
branaplamNovartisPhase 1/2
41
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
onasemnogene abeparvovecNovartisPhase 3
77
onasemnogene abeparvovec-xioiNovartisPhase 3
77
RisdiplamRochePhase 1
33